Trial Profile
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Switching From Salmeterol/Fluticasone to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic COPD Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary) ; Salmeterol/fluticasone propionate
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms FLASH
- Sponsors Novartis; Novartis Pharmaceuticals
- 11 Oct 2018 Status changed from active, no longer recruiting to completed.
- 03 Aug 2018 Results published in the Respirology.
- 27 Nov 2017 According to a Novartis media release, results were presented at the Asian Pacific Society of Respirology (APSR) Congress November 2017.